Ontario Investing $1 Billion to Expand COVID-19 Testing
Breaking News

$925M Sanofi Vaccine Facility In Ontario Will Create 300 High Quality Jobs

Reading Time: 3 minutes

By Investing in Sanofi Province Will Create Hundreds Of Jobs and Increase R&D

The COVID-19 pandemic has highlighted Canada’s in ability to mass produce vaccines at home in the middle of a global crisis. Canada has some of the worlds greatest minds, scientists and technology. Now with the creation of a state of the art vaccine production facility, Canada will be better positioned to produce vaccines at home.

As the Ontario government continues to put their citizens in the best position make it through the pandemic, they continue to work with their Federal counterparts to provide high paying jobs while providing the updated statement below.

“Today marks a great moment for life sciences and vaccine manufacturing in the Province of Ontario and in Canada. This investment, in collaboration with our government partners, demonstrates our shared commitment to strategically grow our domestic industrial biomanufacturing. This new asset means that we can have the additional capacity to continue protecting Canadians’ health and assist in pandemic preparedness in the future.” – Fabien Marino
Vice President Industrial Affairs and Sanofi Pasteur Toronto Site Head

The Ontario government is partnering with the federal government, the City of Toronto and Sanofi, a leading global biopharmaceutical and vaccines company, to expand its Ontario facility to meet growing demand for flu vaccines, boost Canada’s preparedness for future pandemics and create 300 high-quality jobs.

Ontario is investing $55 million through a performance-based loan, toward construction of Sanofi’s $925 million state-of-art vaccine facility to meet growing demand for flu vaccines, specifically for populations at greater risk of influenza. The company is also committing to an average of $79 million a year in research and development in Ontario or more than a half a billion dollars over the life of the agreement. Sanofi will also be leveraging leading scientists in the province giving them the industrial R&D experience that is valuable to companies.

“This is a critical investment as it will create 300 high quality jobs and push Ontario toward becoming less reliant on others for the production of flu and potentially other vaccines,” said Premier Ford. “By supporting companies like Sanofi we will continue to strengthen our excellent pharmaceutical sector and ensure we are prepared for future public health events with Made in Ontario products.”

The investment will enable Sanofi to bulk manufacture Fluzone® High-Dose Quadrivalent Influenza Vaccine, a flu vaccine approved for people 65 years and older, at its historic Connaught site in Toronto. The facility will include industrial scale Formulation, Filling and Packaging, a key requirement for pandemic preparedness.

The project will result in the production of more flu shots in Canada, while strengthening Ontario’s biopharmaceutical industry, making the province a strong candidate for future vaccine production. Through this investment, research and development activities will continue at Sanofi’s Toronto location and there will be expanded opportunities for the agricultural industry value chain.

“It is critical, now more than ever, that we build the capacity to supply Ontario and all of Canada with flu vaccines,” said Vic Fedeli, Minister of Economic Development, Job Creation and Trade. “The support we provide Sanofi will build on this province’s bio-manufacturing capacity, save lives and help prepare us for any future pandemic emergency.”

This new facility is a second large manufacturing mandate for Sanofi at this site. In 2018, Ontario and Sanofi announced another large bulk vaccine manufacturing facility focused on doubling the site’s capacity to produce childhood vaccines.

Sanofi Pasteur, a subsidiary of French headquartered Sanofi, is Ontario’s largest brand name biopharmaceutical company with a full spectrum of R&D, manufacturing, clinical trials, regulatory and quality affairs and distribution operations.

More great reading

TDS News
TDS News
News does not and should not dehumanize people for the sake of financial gains, political favours and social media clout.